Price T Rowe Associates Inc Akebia Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $816 Billion
  • Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 59,900 shares of AKBA stock, worth $56,306. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,900
Previous 59,900 -0.0%
Holding current value
$56,306
Previous $75,000 46.67%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$0.87 - $1.84 $19,923 - $42,136
-22,900 Reduced 27.66%
59,900 $69,000
Q2 2023

Aug 14, 2023
SELL
$0.51 - $1.43 $11,577 - $32,461
-22,700 Reduced 21.52%
82,800 $76,000
Q1 2023

May 15, 2023
SELL
$0.56 - $1.15 $34,384 - $70,610
-61,400 Reduced 36.79%
105,500 $60,000
Q3 2022

Nov 14, 2022
BUY
$0.32 - $0.46 $38,336 - $55,108
119,800 Added 254.35%
166,900 $54,000
Q2 2022

Aug 15, 2022
SELL
$0.32 - $0.67 $4,962 - $10,389
-15,507 Reduced 24.77%
47,100 $17,000
Q1 2022

May 16, 2022
BUY
$0.72 - $2.93 $13,067 - $53,176
18,149 Added 40.82%
62,607 $45,000
Q4 2021

Feb 14, 2022
SELL
$2.26 - $3.34 $7,005 - $10,354
-3,100 Reduced 6.52%
44,458 $100,000
Q3 2021

Nov 15, 2021
BUY
$2.35 - $3.88 $3,607 - $5,955
1,535 Added 3.34%
47,558 $137,000
Q2 2021

Aug 16, 2021
BUY
$2.83 - $4.2 $9,477 - $14,065
3,349 Added 7.85%
46,023 $174,000
Q1 2021

May 17, 2021
SELL
$2.92 - $5.06 $201 - $349
-69 Reduced 0.16%
42,674 $144,000
Q4 2020

Feb 16, 2021
BUY
$2.22 - $3.78 $94,889 - $161,568
42,743 New
42,743 $120,000

Others Institutions Holding AKBA

# of Institutions
127
Shares Held
56.7M
Call Options Held
937K
Put Options Held
743K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $173M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email